Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Indivior PharmaceuticalsINDV +0.36%77 OCF Margin % is 66.76% as of Jun. 2026, which is 535% above its 10-year median of 10.51. GuruFocus rates INDV with a GF Score™ of 77/100 and a GF Value™ of $24.23 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 961 Drug Manufacturers companies, Indivior Pharmaceuticals ranks worse than 77.42% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Indivior Pharmaceuticals's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indivior Pharmaceuticals OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Indivior Pharmaceuticals's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Indivior Pharmaceuticals's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indivior Pharmaceuticals (INDV) has a OCF Margin % of 66.76% as of Jun. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Indivior Pharmaceuticals and its competitors. This is 535% above median its historical median of 10.51. According to the industry distribution chart, Indivior Pharmaceuticals ranks #744 out of 961 companies in the Drug Manufacturers industry, placing it in the top 77.4%.
Is Indivior Pharmaceuticals' OCF Margin % too high?
Indivior Pharmaceuticals' current OCF Margin % of 66.76% is 535% above median its 10-year median of 10.51. The Drug Manufacturers industry median OCF Margin % is 9.92. Indivior Pharmaceuticals' value of 66.76% is 573% above this industry median. Based on the distribution chart, Indivior Pharmaceuticals ranks #744 out of 961 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Indivior Pharmaceuticals has a GF Score™ of 77/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Indivior Pharmaceuticals' OCF Margin % compare to KNSA and AMRX?
According to the Drug Manufacturers industry distribution chart, Indivior Pharmaceuticals ranks #744 out of 961 companies for OCF Margin %. This places Indivior Pharmaceuticals in the lower half of its industry. The industry median OCF Margin % is 9.92. Indivior Pharmaceuticals' value of 66.76% is 573% above this benchmark. While the company's 10-year median is 10.51 vs. the industry median of 9.92, Indivior Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.92, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indivior Pharmaceuticals's current OCF Margin % of 66.76% is 573% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Indivior Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indivior Pharmaceuticals's current OCF Margin % is 66.76%, which is 535% above median its own 10-year median of 10.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indivior Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Indivior Pharmaceuticals (INDV) is currently considered Significantly Overvalued. The stock's GF Value™ is $24.23, compared to a current price of $38.83 — trading 60.3% above its estimated fair value. The current OCF Margin % is 66.76%, which is 535% above median its 10-year median of 10.51 and 573% above the Drug Manufacturers industry median of 9.92. Indivior Pharmaceuticals' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Indivior Pharmaceuticals (INDV), the current OCF Margin % is 66.76% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Indivior Pharmaceuticals (INDV) Overvalued in 2026?
Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued.
The current stock price of $38.83 is trading 60.3% above its estimated GF Value™ of $24.23.
GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for INDV:
OCF Margin %: 66.76% (535% above median its 10-year median of 10.51)
GF Value™: $24.23 vs. price of $38.83 (60.3% above fair value)
Industry Position: 573% above the Drug Manufacturers median (#744 of 961)
No single metric tells the full story. See the INDV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
77GF Score
Get the complete analysis for INDV
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INDV has been successfully added to your 
